Icariin Metabolism by Human Intestinal Microflora

Area of Science:

• Pharmacology
• Microbiology
• Natural Products Chemistry

Background:

• Icariin, a key compound in Epimedii Herba, possesses anti-cancer, anti-inflammatory, and anti-osteoporosis properties.
• Icariin's estrogenic activities are noted, but research findings are inconsistent.
• Understanding icariin metabolism is crucial for its therapeutic applications.

Purpose of the Study:

• To investigate the biotransformation of icariin by human intestinal bacteria.
• To identify icariin metabolites produced by specific gut bacterial strains.
• To provide insights into icariin pharmacokinetics and explain discrepancies in its observed effects.

Main Methods:

• Incubation of icariin with human intestinal microflora and isolated bacterial strains (Streptococcus sp. MRG-ICA-B, Enterococcus sp. MRG-ICA-E, Blautia sp. MRG-PMF-1) under anaerobic conditions.
• Analysis of icariin metabolites using chromatographic techniques.
• Comparison of metabolic pathways among different bacterial strains.

Main Results:

• Icariin was metabolized to icariside II, icaritin, and desmethylicaritin by the tested bacteria.
• Streptococcus sp. MRG-ICA-B and Enterococcus sp. MRG-ICA-E primarily produced icariside II by hydrolyzing the glucose moiety.
• Blautia sp. MRG-PMF-1 further metabolized icariin through icariside II and icaritin to desmethylicaritin.

Conclusions:

• Human intestinal bacteria rapidly transform icariin into icariside II prior to absorption.
• The pharmacokinetics of icariin should consider its major metabolites: icariside II, icaritin, and desmethylicaritin.
• Bacterial metabolism of icariin is key to understanding its variable pharmacological effects and in vitro bioassay results.